Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 12/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18848234 | 0.92 | ACHE (0.36) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL18848370 | 0.85 | CHRNB2 (0.32) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL18792725 | 0.83 | ACHE (0.36) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL1880867 | 0.83 | ACHE (0.36) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL18816756 | 0.80 | ACHE (0.39) | ACHE | |
| SCHEMBL15113723 | 0.80 | CHRNB2 (0.49) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL23125495 | 0.78 | CYP2D6 (0.45) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL18848270 | 0.78 | ACHE (0.42) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL18631734 | 0.78 | ACHE (0.36) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL18848351 | 0.76 | CHRNB2 (0.35) | ACHECHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738620-B2 | Trientine prodrugs, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738620-B2 | Trientine prodrugs, pharmaceutical compositions thereof, and methods of use | Nguyen, Mark Quang (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170129868-A1 | TRIENTINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170129868-A1 | TRIENTINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129868-A1 | TRIENTINE PRODRUGS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | SLC10A1, ABCB11, SLC10A2 | ACHE 2310/4885CHRNB2 4731/4885CHRNB4 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.